.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,780,399

« Back to Dashboard

Details for Patent: 6,780,399

Title: Delivery of stimulants through an inhalation route
Abstract:The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing ephedrine or fenfluramine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of ephedrine or fenfluramine. In a method aspect of the present invention, one of ephedrine or fenfluramine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of ephedrine or fenfluramine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering ephedrine or fenfluramine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of ephedrine or fenfluramine; and, b) a device that forms an ephedrine or fenfluramine containing aerosol from the composition, for inhalation by the mammal.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Molecular Delivery Corporation (Palo Alto, CA)
Filing Date:May 15, 2002
Application Number:10/150,268
Claims:1. A composition for delivery of ephedrine or fenfluramine comprising a condensation aerosol a) formed by volatilizing epredrine or fenfluramine under conditions effective to produce a heated vapor of the drug and condensing the heated vapor of the ephedrine or fenfluramine to form condensation aerosol particles: b) wherein said condensation aerosol particles are characterized by less than 5% ephendrine or fenfluramine degradation products, and c) the aerosol has an MMAD less than 3 microns.

2. The composition according to claim 1, wherein the condensation aerosol particles comprise less than 2.5 percent by weight of ephedrine or fenfluramine degradation products.

3. The composition according to claim 1, wherein the aerosol particles comprise at least 95 percent by weight of ephedrine or fenfluramine.

4. The composition according to claim 3, wherein the aerosol has a mass median aerodynamic diameter less than 2 microns.

5. The aerosol composition according to claim 4, wherein the aerosol particles comprise at least 97 percent by weight of ephedrine or fenfluramine.

6. A method of producing an ephedrine or fenfluramine in an aerosol form comprising: a) volatilizing ephedrine or fenfluramine under conditions effective to produce a heated vapor of the drug, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the ephedrine or fenfluramine comprising less than 5% ephedrine or fenfluramine degradation products and an aerosol having an MMAD less than 3 microns.

7. The method according to claim 6, wherein the aerosol particles are formed at a rate of greater than 0.5 mg/sec.

8. The method according to claim 6, wherein said volatilizing includes heating a coating, which includes ephedrine or fenfluramine and is on a solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize ephedrine or fenfluramine from the coating.

9. The method according to claim 6, wherein the aerosol particles comprise less than 2.5 percent by weight of ephedrine or fenfluramine degradation products.

10. The method according to claim 8, wherein the aerosol particles comprise at least 95 percent by weight of ephedrine or fenfluramine.

11. The method according to claim 10, wherein the aerosol has a mass median aerodynamic diameter less than 2 microns.

12. The method according to claim 11, wherein the aerosol particles comprise at least 97 percent by weight of ephedrine or fenfluramine.

13. A composition for delivery of a stimulant comprising a condensation aerosol a) formed by volatilizing a stimulant under conditions effective to produce a heated vapor of the stimulant and condensing the treated vapor of the stimulant to form condensation aerosol particles; b) wherein said condensation aerosol particles are characterized by less than 5% stimulant degradation products, and c) the aerosol has an MMAD less than 3 microns.

14. A method of producing a stimulant in an aerosol form comprising: a) volatilizing a stimulant under conditions effective to produce a heated vapor of the stimulant, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the stimulant comprising less than 5% stimulant degradation products and an aerosol having an MMAD less than 3 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc